-
COVER STORY
IOPC – Academia & Industry meet
-
EDITORIAL
Consolidation of Peptides and Oligonucleotides (TIDES) in the Pharmaceutical Arena
F. Albericio
-
COMPANY PROFILE
Angelini Pharma – “CRDMO” The new business model for future of the (bio)pharma industry
-
CELL & GENE THERAPY
Why validation is key to the industrialization of cell and gene therapies
S. Wall, S. Ahmed
-
NEWS
-
A WORD WITH
Gilles de Preux, CEO, SSE Holding, Valsynthese
-
COLUMN: CUSTOMER BOND
Pricing is the only moment of truth in value capture Part 1 – Introduction and examples
P. J. F. Gommers
-
COLUMN: CLINICAL TRIALS CHALLENGES
How can sample size contribute to the success of a clinical trial?
E. Pasquali
-
COLUMN: API OF THE MONTH
Abrocitinib
R. Souza
-
Column: REGULATION
Extractable and Leachables in drug products – The toxicological and risk evaluation
A. Conto
-
Panel discussion on OLIGONUCLEOTIDES
K. L. Ackley
-
PANEL DISCUSSION ON PEPTIDES
W. Cabri
-
POST-SHOW – DCAT Week 2022: Welcome back to NYC!
-
COLUMN: QUALITY & SUPPLY CHAIN SECURITY
The future of remote pharma GMP auditing
A. Leckie
-
PHARMA SUPPLY CHAIN
Pharma 4.0 manufacturing optimization using eData
S. M. Wing
-
PHARMA SUPPLY CHAIN
EFPIA and Vaccines Europe position on the European Health Emergency preparedness and Response Authority (HERA)
-
PHARMA SUPPLY CHAIN
Safety at the base of the choice of SIT (specific immunotherapy)
F. Frati, F. Silvestri, A. Pisani, E. Compalati
-
PHARMA SUPPLY CHAIN
Around the Block(chain) – applications in pharma
R. Sharif
-
PHARMA SUPPLY CHAIN
Global campaigns towards local manufacture of anti-HIV/AIDS drugs in continuous flow systems
F. M. Akwi, P. Watts
